Catalpol
(Synonyms: 梓醇; Catalpinoside) 目录号 : GN10094
Catalpol是一种在Rehmannia glutinosa中发现的环烯醚萜苷，具有神经保护、抗糖尿病、抗炎、抗氧化和抗病毒等作用。
Cas No.:2415-24-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Catalpol is an iridoid glycoside found in Rehmannia glutinosa, which has neuroprotective, anti-diabetic, anti-inflammatory, antioxidant and antiviral effects[1, 2]. Catalpol can activate AMP-activated protein kinase to regulate lipid metabolism and reduce hepatic steatosis[3].
In vitro, Catalpol (1, 10, 100μM) treatment of human induced pluripotent stem cells (iPSCs) for 24 h increased cell viability in a dose-dependent manner and reduced intracellular lactate dehydrogenase (LDH) levels and lipid peroxidation levels[4]. Catalpol (10μM) treatment of oligodendrocyte precursor cells (OPCs) promoted OPC proliferation, cell migration and differentiation into mature oligodendrocytes[5].
In vivo, Catalpol (5, 10, 20mg/kg) was intraperitoneally injected into gerbils with cerebral ischemia-reperfusion injury for 3 days, which significantly improved the stroke index, significantly increased brain tissue SOD activity, reduced MDA content, and reduced plasma ET-1 content[6]. Catalpol (25-100mg/kg) was injected intraperitoneally into mice with renal ischemia-reperfusion injury, which reduced the blood urea nitrogen and serum creatinine levels, the expression of PI3K, Akt and eNOS, and inhibited the activity of TNF-α, IL-1β, IL-6 and IL-10[7].
References:
[1] Xia Y, Lu Y W, Hao R J, et al. Catalpol relieved angiotensin II-induced blood–brain barrier destruction via inhibiting the TLR4 pathway in brain endothelial cells[J]. Pharmaceutical Biology, 2022, 60(1): 2210-2218.
[2] Bai Y, Zhu R, Tian Y, et al. Catalpol in diabetes and its complications: a review of pharmacology, pharmacokinetics, and safety[J]. Molecules, 2019, 24(18): 3302.
[3] Tian X, Ru Q, Xiong Q, et al. Catalpol attenuates hepatic steatosis by regulating lipid metabolism via AMP‐activated protein kinase activation[J]. BioMed Research International, 2020, 2020(1): 6708061.
[4] Yang L, Feng X, Li Y, et al. Therapeutic efficacy of catalpol against apoptosis in cardiomyocytes derived from human induced pluripotent stem cells[J]. AMB Express, 2020, 10(1): 56.
[5] Yuan C X, Chu T, Liu L, et al. Catalpol induces oligodendrocyte precursor cell-mediated remyelination in vitro[J]. American Journal of Translational Research, 2015, 7(11): 2474.
[6] Liu Y, Li P, Suo J, et al. Catalpol provides protective effects against cerebral ischaemia/reperfusion injury in gerbils[J]. Journal of Pharmacy and Pharmacology, 2014, 66(9): 1265-1270.
[7] Zhu J, Chen X, Wang H, et al. Catalpol protects mice against renal ischemia/reperfusion injury via suppressing PI3K/Akt-eNOS signaling and inflammation[J]. International Journal of Clinical and Experimental Medicine, 2015, 8(2): 2038.
Catalpol是一种在Rehmannia glutinosa中发现的环烯醚萜苷，具有神经保护、抗糖尿病、抗炎、抗氧化和抗病毒等作用[1, 2]。Catalpol能够激活AMP活化蛋白激酶调节脂代谢减轻肝脂肪变性[3]。
在体外，Catalpol（1, 10, 100μM）处理人诱导多能干细胞（iPSC）24h，以剂量依赖性方式提高了细胞活力，降低了细胞内乳酸脱氢酶（LDH）水平和脂质过氧化水平[4]。Catalpol（10μM）处理少突胶质细胞前体细胞（OPC），促进了OPC增殖、细胞迁移和分化为成熟的少突胶质细胞[5]。
在体内，Catalpol（5, 10, 20mg/kg）通过腹腔注射治疗脑缺血再灌注损伤沙鼠3天，显著改善了卒中指数，显著提高了脑组织SOD活性，降低了MDA含量，降低了血浆ET-1含量[6]。Catalpol（25-100mg/kg）通过腹腔注射治疗肾缺血再灌注损伤小鼠，降低了小鼠的血尿素氮和血清肌酐水平，降低了PI3K、Akt和eNOS的表达，抑制了TNF-α、IL-1β、IL-6和IL-10的活性[7]。
| Cell experiment [1]: | |
Cell lines | Human-induced pluripotent stem cells (iPSCs) |
Preparation Method | The study included five groups: Group I, normal control, human iPSCs incubated with dimethyl sulfoxide (DMSO) for 24h; Group II, treatment control, human iPSCs incubated with 8 µM aconitine for 24h; Group III, low-dose treatment, human iPSCs incubated with 8 µM aconitine and 1µM Catalpol for 24h; Group IV, medium-dose treatment, human iPSCs incubated with 8µM aconitine and 10µM Catalpol for 24h; and Group V, high-dose treatment, human iPSCs incubated with 8µM aconitine and 100µM Catalpol for 24h. |
Reaction Conditions | 1, 10, 100μM; 24h |
Applications | Compared with the treatment control group, Catalpol supplementation (1, 10, and 100µM) increased iPSC cell viability by 7.5, 27.3, and 65.8%, respectively; reduced the LDH levels by 10.4, 31.3, and 75.2%, respectively; and reduced the lipid peroxidation levels by 7.7, 33.0, and 62.6%, respectively. |
| Animal experiment [2]: | |
Animal models | Mongolian gerbils |
Preparation Method | A gerbil model of CI/R was prepared by bilateral common carotid occlusion for 10min followed by 6h reperfusion. Catalpol (5, 10 or 20mg/kg per day) was injected intraperitoneally for 3 days before the carotid occlusion. Stroke index was measured during the reperfusion. The contents of endogenous neuropeptides, endothelin-1 (ET-1) and calcitonin gene-related peptide in plasma were evaluated by radioimmunoassay. Superoxide dismutase (SOD) and malondialdehyde (MDA) in brain tissue homogenate were also examined. |
Dosage form | 5, 10, 20mg/kg; 3 days; i.p. |
Applications | Catalpol significantly improved the stroke index compared with CI/R control group. Catalpol significantly increased the activity of SOD at the doses of 10 and 20mg/kg, decreased the brain MDA content and the plasma level of ET-1 at the doses of 10 and 20mg/kg. |
References: | |
| Cas No. | 2415-24-9 | SDF | |
| 别名 | 梓醇; Catalpinoside | ||
| 化学名 | (2S,3R,4S,5S,6R)-2-[[(1aS,1bS,2S,5aR,6S,6aS)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bH-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| Canonical SMILES | C1=COC(C2C1C(C3C2(O3)CO)O)OC4C(C(C(C(O4)CO)O)O)O | ||
| 分子式 | C15H22O10 | 分子量 | 362.33 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7599 mL | 13.7996 mL | 27.5991 mL |
| 5 mM | 0.552 mL | 2.7599 mL | 5.5198 mL |
| 10 mM | 0.276 mL | 1.38 mL | 2.7599 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet